An open label, single arm, prospective clinical study to evaluate liver safety and tolerability of PUREMERIC™ (standardized extract from Curcuma longa) in healthy subjects - ScienceDirect
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study - The Lancet Haematology
An Open-label, Single-arm Study of CRYO2 for Debulking at the Site of Central Airway Obstruction or Stenosis | In Vivo
A single-arm open-label clinical trial of autologous epidermal cell transplantation for stable vitiligo: A 30-month follow-up. | Semantic Scholar
ACURATE neo clinical trials - Boston Scientific
CONSORT flowchart for A single-arm, open-label, phase 2 clinical trial... | Download Scientific Diagram
A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus - Journal of Dermatological Science
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study - The Lancet Respiratory Medicine
![PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/bd292c301c51a1f717d8f0c14788762c69120a87/4-Figure1-1.png "PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar")
PDF] An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. | Semantic Scholar
A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis - Gynecologic Oncology
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study - European Journal of Cancer
New approaches to clinical trials: Adaptive designs - EUPATI Toolbox
Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care - Cytotherapy
Effect of Facial Cosmetic Acupuncture on Facial Elasticity: An Open-Label, Single-Arm Pilot Study – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis - ScienceDirect
The study was design as single-arm open-label trial consisting of a 14... | Download Scientific Diagram
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open -label, phase II study (CheckMate 172) - European Journal of Cancer
Evaluation of apremilast in chronic pruritus of unknown origin: A proof‐of‐concept, phase 2a, open‐label, single‐arm clinical trial - Clark - 2020 - Health Science Reports - Wiley Online Library
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial - The Lancet Oncology
3 month randomised double blind, placebo-controlled phase followed by a 24-month open-label, single-arm phase. The primary endpoint of the trial was to compare the efficiency (4) - Debra Ireland
PLOS ONE: Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)—An open-label, single-arm study
PLOS ONE: A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
Study 079 An OpenLabel SingleArm Phase 2 Trial
